AR070415A1 - Derivados de 3-alquil-piperazina y usos de los mismos - Google Patents

Derivados de 3-alquil-piperazina y usos de los mismos

Info

Publication number
AR070415A1
AR070415A1 ARP090100482A ARP090100482A AR070415A1 AR 070415 A1 AR070415 A1 AR 070415A1 AR P090100482 A ARP090100482 A AR P090100482A AR P090100482 A ARP090100482 A AR P090100482A AR 070415 A1 AR070415 A1 AR 070415A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
3alkyl
Prior art date
Application number
ARP090100482A
Other languages
English (en)
Inventor
Robert James Weikert
Ryan Craig Schoenfeld
Matthew C Lucas
David Scott Carter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR070415A1 publication Critical patent/AR070415A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan también composiciones farmacéuticas, métodos de empleo y métodos de obtencion de los compuestos. utiles para depresion y ansiedad. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo, en la que: m es un numero de 1 a 3; n es un numero de 0 a 2; Ar es: indolilo opcionalmente sustituido; indazolilo opcionalmente sustituido; azaindolilo opcionalmente sustituido; azaindazolilo opcionalmente sustituido; 2,3-dihidro-indolilo opcionalmente sustituido; benzotiofenilo opcionalmente sustituido; bencimidazolilo opcionalmente sustituido; benzoxazolilo opcionalmente sustituido; benzotiazolilo opcionalmente sustituido; quinolinilo opcionalmente sustituido; isoquinolinilo opcionalmente sustituido; naftalenilo opcionalmente sustituido; o fenilo opcionalmente sustituido; uno de X, Y y Z es N y los demás son CRa o X, Y y Z son CRa en el que cada Ra es con independencia hidrogeno o R7; R1 es: hidrogeno; alquilo C1-6 o un grupo protector de amina; R2 es: alquilo C3-6; alcoxi C1-6-alquilo C1-3; hidroxi-alquilo C1-6; cicloalquilo C3-6; cicloalquil C3-6-alquilo C1-3; cicloalquiloxi C3-6-alquilo C1-3; cicloalquil C3-6-alcoxi C1-3-alquilo C1-3; arilo; heteroarilo; ariloxi-alquilo C1-3; heteroariloxi-alquilo C1-3; heterociclilo; o heterociclil-alquilo C1-3; R3 es: hidrogeno; o alquilo C1-6; o R2 y R3 junto con el átomo al que están unidos pueden formar un cicloalquilo C3-6; R4 es: hidrogeno; o alquilo C1-6; o R2 y R4 junto con los átomos a los que están unidos pueden formar un anillo heterocíclico de cinco o seis eslabones.
ARP090100482A 2008-02-15 2009-02-12 Derivados de 3-alquil-piperazina y usos de los mismos AR070415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2897808P 2008-02-15 2008-02-15

Publications (1)

Publication Number Publication Date
AR070415A1 true AR070415A1 (es) 2010-04-07

Family

ID=40521728

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100482A AR070415A1 (es) 2008-02-15 2009-02-12 Derivados de 3-alquil-piperazina y usos de los mismos

Country Status (15)

Country Link
US (1) US7998963B2 (es)
EP (1) EP2254884B1 (es)
JP (1) JP2011512340A (es)
KR (1) KR20100101171A (es)
CN (1) CN101952278A (es)
AR (1) AR070415A1 (es)
AU (1) AU2009214190A1 (es)
BR (1) BRPI0908807A2 (es)
CA (1) CA2713378A1 (es)
CL (1) CL2009000317A1 (es)
IL (1) IL206951A0 (es)
MX (1) MX2010008778A (es)
PE (1) PE20091470A1 (es)
TW (1) TW200938533A (es)
WO (1) WO2009101018A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2507215A1 (en) * 2009-12-04 2012-10-10 F. Hoffmann-La Roche AG Diphenyl azepine derivatives as monoamine reuptake inhibitors
CN103508981A (zh) * 2012-06-18 2014-01-15 北京美倍他药物研究有限公司 新的哌嗪衍生物及其医药用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950872A (en) 1961-03-17 1964-02-26 Soc Ind Fab Antibiotiques Sifa Substituted pyridyl-ethyl-piperazines
US6967201B1 (en) * 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
TR200400510T4 (tr) * 2000-08-03 2004-08-23 Pfizer Products Inc. Diazabisiklooktan türevleri ve bunların terapötik kullanımları
EP1368348B1 (en) * 2001-03-02 2005-01-19 Neurosearch A/S Novel 2,5-diazabicyclo(2.2.1)heptane derivatives
KR20040012851A (ko) 2001-05-22 2004-02-11 뉴로젠 코포레이션 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체
YU96103A (sh) * 2001-06-07 2006-08-17 F.Hoffmann-La Roche Ag. Novi derivati indola sa afinitetom za 5-ht6 receptor
BR0210291A (pt) * 2001-06-11 2004-07-13 Biovitrum Ab Compostos de sulfonamida substituìdos, processo para sua preparação e seu uso como medicamento para o tratamento de distúrbios do sistema nervoso central, obesidade e diabetes do tipo ii
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
MXPA04009318A (es) * 2002-03-27 2005-01-25 Glaxo Group Ltd Derivados de quinolina y su uso como ligados 5-ht6.
JP2005289816A (ja) * 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
WO2004080407A2 (en) 2003-03-07 2004-09-23 Predix Pharmaceuticals Holdings, Inc. New serotonin modulating compounds and uses therefor
BRPI0414136A (pt) * 2003-09-04 2006-10-31 Aventis Pharma Inc indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
WO2005082887A1 (ja) * 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
EP1761512A1 (en) * 2004-06-18 2007-03-14 Neurosearch A/S Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1773653A1 (en) 2004-07-01 2007-04-18 Ringprop Trading Limited Shroud or ring propeller blade interface
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
KR20080048550A (ko) * 2005-09-23 2008-06-02 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
US7812162B2 (en) * 2006-04-26 2010-10-12 The University Of Montana Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
US8530475B2 (en) * 2006-05-18 2013-09-10 Janssen Pharmaceutica Nv Bridged aryl piperazines derivatives useful for the treatment of CNS, GI-urinary and reproductive disorders
MX2009001494A (es) * 2006-08-07 2009-04-23 Albany Molecular Res Inc 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
BRPI0715341A2 (pt) * 2006-08-17 2013-11-26 Hoffmann La Roche Derivados de aril piperazina e usos dos mesmos
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬

Also Published As

Publication number Publication date
TW200938533A (en) 2009-09-16
CL2009000317A1 (es) 2010-02-26
WO2009101018A2 (en) 2009-08-20
BRPI0908807A2 (pt) 2015-07-28
MX2010008778A (es) 2010-08-30
EP2254884A2 (en) 2010-12-01
IL206951A0 (en) 2010-12-30
WO2009101018A3 (en) 2010-01-28
JP2011512340A (ja) 2011-04-21
CA2713378A1 (en) 2009-08-20
KR20100101171A (ko) 2010-09-16
PE20091470A1 (es) 2009-09-24
CN101952278A (zh) 2011-01-19
AU2009214190A1 (en) 2009-08-20
US7998963B2 (en) 2011-08-16
US20090209553A1 (en) 2009-08-20
EP2254884B1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
RS54910B1 (sr) Jedinjenje indola i njegova upotreba u farmaciji
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
DOP2010000046A (es) Compuestos de biciclolactama sustituida
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
RS54708B1 (en) ARYLETINYL DERIVATIVES
AR054797A1 (es) Derivados de quinolina, composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de infecciones virales por virus de la familia flaviviridae, tal como hcv.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR062405A1 (es) Derivados de isoindol
AR065863A1 (es) Derivados de imidazolidinona
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
CO6020016A1 (es) Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
RS51462B (en) TRIAZOLOPYRIDINE CARBOXAMID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure